KOREA
Contract Service
E11
Contract Service
Analytical Equipment, Cell & Gene therapy, Stability Testing of Drugs
NEXEL Co., Ltd. was incorporated in 2012 as a spin-off from Korea University in Seoul, South Korea. NEXEL is a specialist in embryonic stem cell and induced pluripotent stem cell(iPSC) technology.
NEXEL is a world leader in iPSC (induced Pluripotent Stem Cell) technology as the first Korean company to license iPS technology and setting a new paradigm in the in vitro toxicity field through successful commercialization of iPS-derived cells which mimic actual human functionality. Furthermore, we are investing our expertise into the discovery and development of new drug candidates based on proteins and peptides derived from stem cell technology.
NEXEL is a world leader in iPSC (induced Pluripotent Stem Cell) technology as the first Korean company to license iPS technology and setting a new paradigm in the in vitro toxicity field through successful commercialization of iPS-derived cells which mimic actual human functionality. Furthermore, we are investing our expertise into the discovery and development of new drug candidates based on proteins and peptides derived from stem cell technology.
